Plus Therapeutics announced on February 24, 2025, key leadership appointments for its wholly-owned subsidiary, CNSide Diagnostics, LLC. Russell Bradley was named President and General Manager of CNSide, and Dr. Jonathan Stein was appointed CNSide Medical Director.
Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley also joined the CNSide Board of Directors. Mr. Bradley brings over 30 years of leadership experience in diagnostics and life sciences, with a track record of launching and scaling market-leading diagnostic platforms.
Dr. Stein has over 20 years of expertise in molecular diagnostics, assay development, and regulatory compliance. These appointments are crucial as CNSide Diagnostics prepares for a pilot market introduction in the current quarter and aims to fully capitalize its operations for initial launch plans in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.